Related Experiment Videos
Age-related differences in the protein binding of quinidine
Insights
Serum protein binding of quinidine is lower in newborns and infants, potentially increasing drug activity. This study analyzed binding in pediatric patients across different age groups.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Chemistry
Background:
- Serum protein binding influences drug efficacy and safety.
- Understanding age-related changes in drug binding is crucial for pediatric dosing.
Purpose of the Study:
- To determine the in vitro serum protein binding of quinidine in pediatric patients.
- To investigate the relationship between age and quinidine protein binding.
Main Methods:
- In vitro analysis of serum protein binding of quinidine.
- Study included 26 pediatric patients across three age groups: cord blood (Group I), 8-18 months (Group II), and over 2 years (Group III).
Main Results:
- The percentage of free quinidine was significantly higher in newborns (39.2%) compared to infants (24.4%) and older children (16.6%).
- A statistically significant increase in quinidine protein binding was observed with advancing age (p < 0.0001).
Conclusions:
- Quinidine protein binding is diminished in neonates and young infants.
- Lower protein binding in younger pediatric populations may lead to enhanced quinidine activity and necessitate dose adjustments.
Abstract:
The in vitro serum protein binding of quinidine was determined in 26 pediatric patients. Group I consisted of 6 cord blood samples obtained at the time of delivery, group II of 8 infants aged 8-18 months, and group III of 12 children over the age of 2 years. The percentage of free quinidine in group I was 39.2 +/- 10.8, group II 24.4 +/- 10.6 and group III 16.6 +/- 6.5, demonstrating a larger proportion of unbound quinidine in the newborn group and an increase in protein binding with age (p less than 0.0001). Therefore, the protein binding of quinidine is diminished in the neonate and young infant and may result in enhanced quinidine activity.